J&J Gene Therapy for Rare, Progressive Vision-Loss Disorder Fails Phase 3 Test

J&J Gene Therapy for Rare, Progressive Vision-Loss Disorder Fails Phase 3 Test

Johnson & Johnson’s gene therapy for X-linked retinal pigmentosa did not meet the main vision goal of a pivotal study. J&J secured full rights to the program from gene therapy biotech MeiraGtx in 2023. The post J&J Gene Therapy for Rare, Progressive Vision-Loss Disorder Fails Phase 3 Test appeared first on MedCity News.

J&J gene therapy treatment fails primary endpoints

ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

J&J's eye disease gene therapy bota-vec fails in Phase 3 trial

Johnson & Johnson’s gene therapy for a genetic disease that leads to vision loss called X-linked retinitis pigmentosa (XLRP) failed a pivotal trial, according to an update to a J&J healthcare provider website. At one ...